Prognostic Implications of Quantifying Vasoactive Medications in Cardiogenic Shock

Affiliations

• ¹ Warren Alpert Medical School of Brown University, Providence, RI; Lifespan Cardiovascular Institute, Providence, RI.
• ² Tufts University School of Medicine, Boston, MA.
• ³ Inova Schar Heart and Vascular Institute, Inova Fairfax Campus, Falls Church, VA.
• ⁴ Baylor Scott & White Health, Temple, TX.
• ⁵ Cardiovascular Institute at Allegheny Health Network, Pittsburgh, PA.
• ⁶ Providence Heart Institute, Portland, OR.
• ⁷ University of Texas Southwestern Medical Center, Dallas TX.
• ⁸ Columbia University Medical Center, New York, NY.
• ⁹ Beth Israel Deaconess Medical Center, Boston, MA.
• ¹⁰ Baylor Scott & White Health, Dallas, TX.
• ¹¹ University of Pittsburgh Medical Center, Pittsburgh, PA.
• ¹² Houston Methodist Research Institute, Houston, TX.
• ¹³ Institute for Advanced Cardiac Care, Medical City Healthcare, Dallas, TX.
• ¹⁴ University of Chicago Pritzker School of Medicine, Chicago, IL.
• ¹⁵ University of Oklahoma Health Science Center, Oklahoma City, OK.
• ¹⁶ Maine Medical Center, Portland, ME.
• ¹⁷ Massachusetts General Hospital, Boston, MA.
• ¹⁸ Thomas Jefferson University Hospital, Philadelphia, PA.
• ¹⁹ Northwestern Medicine, Chicago, IL.
• ²⁰ University Hospital of Düsseldorf, Düsseldorf, Germany.
• ²¹ Cardiovascular Research Foundation, New York, NY.
• ²² Tufts University School of Medicine, Boston, MA. Electronic address: nkapur@tuftsmedicalcenter.org.